Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.36 |
| ▸ | MPC2 | O95563 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14213709 | 0.91 | PPARG (0.38) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14299373 | 0.91 | PPARG (0.49) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL17540550 | 0.89 | PPARG (0.37) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14213636 | 0.81 | FFAR1 (0.38) | PPARGFFAR1 | |
| SCHEMBL14213648 | 0.81 | PPARG (0.51) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14213631 | 0.81 | PPARG (0.51) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14213649 | 0.80 | PPARG (0.40) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14299374 | 0.78 | FFAR1 (0.38) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14213710 | 0.77 | PPARG (0.41) | PPARGFFAR1MPC2CYP2C8CYP2C9 | |
| SCHEMBL14299377 | 0.77 | PPARG (0.49) | PPARGFFAR1MPC2CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912335-B2 | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-20120309975-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309975-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | PPARD, PPARG, PPARA | PPARG 2/4885FFAR1 51/4885MPC2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.